Willem P.C. Duyvesteyn:

Education: Ingenieurs Degree (summa cum laude), Delft University of Technology, Delft, the Netherlands, 1968.

Mr. Duyvesteyn is currently the President of The Technology Store, Inc., a private U.S. corporation. T.T.S. is engaged in the commercialization of various technologies for the minerals industry. He has held the position of Vice President and General Manager Minerals Technology at BHP Billiton. Prior to his prolific work at BHP Billiton, he spent 10 years with Amax Inc. (Phelps Dodge Corporation) and five years at AngloAmerican. He is a member of AIME's Society of Mining and Metallurgical Engineers, the American Institute of Chemical Engineers, the Canadian Institute of Mining and the UK Institute for Mining and Metallurgy. He is the author of over 25 technical publications in the field of mineral processing and extractive metallurgy. He holds over 30 US and foreign patents. In 1997, he was awarded the Gold Fields Gold Medla from the UK Institute for Mining and Metallurgy.

William J. Halden

Education: BA, University of Texas, 1976; MD, Baylor College of Medicine, 1980; Internship in Internal Medicine, University of Utah, 1981; Resident in Diagnostic Radiology, University of Utah, 1984; Board Certified, Diagnostic Radiology, 1984; Fellowship in Interventional Radiology, John Hopkins, 1986.

For over 15 years, Dr. Halden has been a practicing interventional radiologist. He is currently a practicing interventional radiologist in the State of Utah and a partner in Utah Radiology Associates, Inc., one of the largest radiological practices in the country.

Charles "Chuck" House

Education: BS Eng. Physics, California Institute of Technology, 1962; MS EE, Stanford University, 1964; MA History of Science, Univ. of Colorado, 1970; MBA (Strategic Studies), Western Behavioral Sciences Institute, 1985 (now University of California, San Diego).

Chuck House is the Science Policy and Societal Impact Director for Intel. Chuck joined Intel via Dialogic, first as President of Spectron Microsystems, which built real-time operating systems and development tools for DSP chipsets, and then as Executive Vice President of Core Systems Development and Communications Research. He was honored by the Computer Museum and Smithsonian for inclusion in the Computing Pioneers exhibit and book about the 200 U.S. computing leaders, "Wizards and their Wonders." Chuck served with Hewlett-Packard from 1962 to 1991, first as a member of the technical staff, and then as founder and, later as general manager of Hewlett-Packard's Logic Systems division. He then served for 10 years as the company's first corporate engineering director and general manager of HP's Software Engineering Systems division. His work at Informix was instrumental to what was acknowledged as the top turnaround story in 1994 by Forbes, Fortune and Barron's magazines. Chuck has received several patents and key awards including the Electronics Award of Achievement, 1977; Hewlett-Packard Award of Defiance, 1982; Computer Design Hall of Fame, 1984; IDSA Gold Medals for Software (MOTIF, VUE), 1989, 1990; IEEE Fellow (for Logic Analysis), 1990; EE Times Historic Contributor Award, 1997; IEEE 3rd Millennium Achievement Award, 2000.

Roy L. Silverstein, M.D.:

Education: MD, Emory University School of Medicine, 1979, Certified Internal Medicine, 1982; Hematology, 1984; Oncology, 1985

Dr. Silverstein is currently Department of Medicine Chief, Hematology and Oncology, Weill Medical College of Cornell University. He is a Professor of Medicine in Microbiology and a Professor of Cell Biology and Genetics. Dr. Silverstein is actively involved in research of the molecular pathogenesis of thrombosis, atherosclerosis, and inflammation. His work has been published in leading medical journals such as the Journal of Cell Biology and the Journal of Biological Chemistry.

Michael J. Stamos, M.D.:

Education: MD, Case Western Res. U., 1985; Intern 1985-86; Resident General Surgery, 1986-90 (both at University Miami/JMH); Fellow Colon and Rectal Surgery, Ochsner Medical Clinic, 1990-91.

Dr. Stamos has numerous current appointments including Chief, Division of Colon and Rectal Sugery; Medical Director, Ambulatory Sugery, Associate Residency Program Director, General Surgery, all at Harbor-UCLA Medical Center, Torrance CA 1992-present. He is also Chief, Colon and Rectal Surgery, VA Medical Center, West Los Angeles, CA, 1991-present. His also Associate Professor, Department of Surgery, UCLA, 1997-present. Finally, he is the Vice Chairman, Board of Directors for Faculty Practice Paln at Harbor-UCLA Medical Center, Torrance, CA 2001-present. Dr. Stamos is a distinguished practitioner, scholar, researcher, teacher and lecturer. He is the recipient of numerous awards and honors. He has been referenced in publications such as "Best Doctors in America" and "America's Top Doctors." His work has been referenced in 30 scientific publications and 11 medical abstracts. He also has contibuted to over 20 books and is a frequent invited lecturer internationally.

Theodore H. Stanley, M.D.:

Education: MD, Columbia P&S, 1965; Intern, 1965-66, Resident Surgery 1966-67, ( both at University of Michigan); Resident Anesthesiology, Columbia Presbyterian Medical Center, 1968-70; Fellow Surgery, University of Utah, 1967-68.

Dr. Stanley has been Director of Research at the University of Utah for over 20 years and is internationally known for his developmental work on opioids, other intravenous anesthetics and novel delivery techniques. In 1985, he co-founded Anesta (NASDAQ), a major drug delivery company with two FDA approved products, fentanyl Oralet (oral transmucosal fentanyl citrate) and Actiq. Dr. Stanley was Chairman of the Board of Anesta when Anesta was bought by Cephalon. He is an often-invited speaker on Anesthesiology and the future of drug delivery topics throughout the world.

Brian D. Stoll, M.D.:

Education: MD, University of Kentucky College of Medicine, 1987; Intern, Roanoke Memorial Hospital; Resident, 1987-1988, Resident radiation Oncology, University of Kentucky, 1988-1991.

Dr. Stoll is a practicing radiation oncologist in Louisville, Kentucky.

Tin-Chuen Yeung, PhD:

Education: Master of Management Degree, Kellogg Graduate School of management, 1987; PhD, Pharmacology and Philosophy, State University of New York at Stony Brook, 1980; B.S., Biochemistry, State University of New York at Stony Brook, 1975.

Dr. Yeung is currently employed as a patent agent in science, healthcare and technology. From 1995-1998, he held the position of Director of Corporate Development at Baxter International Inc. (NYSE:BAX) where he was responsible for management of business transactions, developing new initiatives, managment of bankers, market and financial analysis, negotiations, due diligence and presentations. From 1983-1991, Dr Yeung was employed at Monsanto Company as Manager of Business Ventures in the Nutrasweet Division. where he was responsible for identification, evaluation and devlopment of new businesses. In addition. his responsibilities included market research, commercialization of new products and new technologies in food biotechnology and nutraceuticals. His work has been featured in over 15 publications and/or presentations during his career.